Tarsus Pharmaceuticals Inc (TARS) — Financial Flexibility Index

Latest as of June 2026: 0.27x

Tarsus Pharmaceuticals Inc (TARS) has a Financial Flexibility Index of 0.27x as of June 2026. Free cash flow of $70.84 Million (operating CF $66.77 Million minus capex $4.07 Million) represents 0% of total liabilities ($264.41 Million). Check TARS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

0.27x
Free Cash Flow / Total Liabilities

Free Cash Flow

$70.84 Million
Operating CF − Capex

Total Liabilities

$264.41 Million
USD

Capital Expenditures

$4.07 Million
USD

Tarsus Pharmaceuticals Inc Financial Flexibility Index (2018–2025)

Historical Financial Flexibility Index trend for Tarsus Pharmaceuticals Inc across 8 annual periods. For the full cash flow conversion analysis, see TARS cash generation efficiency.

Annual Financial Flexibility Index for Tarsus Pharmaceuticals Inc (2018–2025)

Year-by-year free cash flow to debt coverage for Tarsus Pharmaceuticals Inc. Explore Tarsus Pharmaceuticals Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -0.01x $-2.59 Million $-12.45 Million $218.73 Million ▲ +97.8%
2024 -0.53x $-81.46 Million $-83.03 Million $152.46 Million ▲ +67.3%
2023 -1.63x $-111.99 Million $-117.49 Million $68.50 Million ▼ -17.8%
2022 -1.39x $-48.52 Million $-49.03 Million $34.96 Million ▼ -489.9%
2021 0.36x $4.33 Million $3.75 Million $12.18 Million ▲ +110.3%
2020 -3.45x $-20.68 Million $-21.14 Million $5.99 Million ▼ -6246.8%
2019 -0.05x $-3.50 Million $-3.67 Million $64.32 Million ▲ +82.7%
2018 -0.31x $-1.18 Million $-1.18 Million $3.74 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities